92 related articles for article (PubMed ID: 2616893)
1. Inhibition of neoplastic growth by N-homocysteine thiolactonyl retinamido cobalamin.
McCully KS; Tzanakakis GN; Vezeridis MP
Res Commun Chem Pathol Pharmacol; 1989 Oct; 66(1):117-22. PubMed ID: 2616893
[TBL] [Abstract][Full Text] [Related]
2. Effect of the synthetic N-homocysteine thiolactonyl derivatives, thioretinaco, thioretinamide, and thioco on growth and lactate production by malignant cells.
McCully KS; Tzanakakis GN; Vezeridis MP
Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):125-8. PubMed ID: 1439176
[No Abstract] [Full Text] [Related]
3. Chemopreventive effect of N-homocysteine thiolactonyl retinamido cobalamin on carcinogenesis by ethyl carbamate in mice.
McCully KS; Vezeridis MP
Proc Soc Exp Biol Med; 1989 Sep; 191(4):346-51. PubMed ID: 2771961
[TBL] [Abstract][Full Text] [Related]
4. Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism.
McCully KS
Ann Clin Lab Sci; 1994; 24(1):27-59. PubMed ID: 8147567
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide.
McCully KS; Olszewski AJ; Vezeridis MP
Atherosclerosis; 1990 Aug; 83(2-3):197-206. PubMed ID: 2242097
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine thiolactone metabolism in malignant cells.
McCully KS
Cancer Res; 1976 Sep; 36(9 pt.1):3198-202. PubMed ID: 975084
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic activity of a rhodium trichloride complex of oxalyl homocysteine thiolactone.
McCully KS; Vezeridis MP
Cancer Invest; 1987; 5(1):25-30. PubMed ID: 3580945
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine thiolactone, N-homocysteine thiolactonyl retinamide, and platelet aggregation.
McCully KS; Carvalho AC
Res Commun Chem Pathol Pharmacol; 1987 Jun; 56(3):349-60. PubMed ID: 3628965
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine, Thioretinaco Ozonide, and Oxidative Phosphorylation in Cancer and Aging: A Proposed Clinical Trial Protocol.
McCully KS
Methods Mol Biol; 2019; 1866():285-310. PubMed ID: 30725425
[TBL] [Abstract][Full Text] [Related]
10. Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells.
Kreis W; Goodenow M
Cancer Res; 1978 Aug; 38(8):2259-62. PubMed ID: 667821
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Effects of methylcobalamin on the proliferation of androgen-sensitive or estrogen-sensitive malignant cells in culture and in vivo.
Nishizawa Y; Yamamoto T; Terada N; Fushiki S; Matsumoto K; Nishizawa Y
Int J Vitam Nutr Res; 1997; 67(3):164-70. PubMed ID: 9202976
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive and antineoplastic activity of N-homocysteine thiolactonyl retinamide.
McCully KS; Vezeridis MP
Carcinogenesis; 1987 Oct; 8(10):1559-62. PubMed ID: 3652391
[TBL] [Abstract][Full Text] [Related]
14. Chemical pathology of homocysteine. III. Cellular function and aging.
McCully KS
Ann Clin Lab Sci; 1994; 24(2):134-52. PubMed ID: 8203822
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine thiolactone in arteriosclerosis and cancer.
McCully KS; Vezeridis MP
Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):107-19. PubMed ID: 3353575
[TBL] [Abstract][Full Text] [Related]
16. Chemical pathology of homocysteine. V. Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases.
McCully KS
Ann Clin Lab Sci; 2011; 41(4):301-14. PubMed ID: 22166499
[TBL] [Abstract][Full Text] [Related]
17. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
18. [The proliferation inhibition and differentiation inducing effects of all-trans retinoic acid on human pancreatic adenocarcinoma cell line JF-305].
Liu D; Wang Y; Wang B
Zhonghua Wai Ke Za Zhi; 1997 Mar; 35(3):153-5. PubMed ID: 10374522
[TBL] [Abstract][Full Text] [Related]
19. Tumor therapy by deprivation of L-methionine: rationale and results.
Kreis W
Cancer Treat Rep; 1979 Jun; 63(6):1069-72. PubMed ID: 466646
[TBL] [Abstract][Full Text] [Related]
20. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
